N/A
Average AnalystN/A
Top AnalystSlightly Bearish
Stock Target AdvisorN/A
Average UserUSD 0.13
-0.01 (-5.26%)
USD 9.14M
0.47M
USD 0.00
Based on the AIM ImmunoTech Inc stock forecast from 0 analysts, the average analyst target price for AIM ImmunoTech Inc is not available over the next 12 months. AIM ImmunoTech Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AIM ImmunoTech Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, AIM ImmunoTech Inc’s stock price was USD 0.13. AIM ImmunoTech Inc’s stock price has changed by +4.91% over the past week, -11.33% over the past month and -65.00% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.